CAMBRIDGE, England & VICTORIA, Australia--(BUSINESS WIRE)--Mundipharma International Corporation Limited (Mundipharma) and Medical Developments International Limited (ASX:MVP) today announced that they have entered into a License, Development and Commercialisation Agreement for Penthrox® (low dose methoxyflurane) in Europe, as a self-inhaled analgesic for the treatment of emergency pain. Mundipharma will have exclusive product rights in 39 European markets including France, Germany, Italy and S
| < Prev | Next > |
|---|
